我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

重组人脑钠尿肽治疗急性失代偿心力衰竭中不同水钠潴留程度患者的疗效

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第5期
页码:
719-723
栏目:
临床研究
出版日期:
2010-06-22

文章信息/Info

Title:
Efficacy study of recombinant human brain natriuretic peptide in patients with acute decompensated heart failure and different severities of H2O/Na+ retention
作者:
陶博; 曹丰; 赵志敬; 李伟杰; 王海昌
第四军医大学西京医院心内科，陕西 西安 710032
Author(s):
TAO Bo;  CAO Feng;  ZHAO Zhi-jing;  LI Wei-jie;  WANG Hai-chang
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
关键词:
脑钠尿肽; 心力衰竭; 失代偿性; 血流动力学
Keywords:
brain natriuretic peptide;  decompensated heart failure;  hemodynamics
分类号:
R541.7
DOI:
-
文献标识码:
A
摘要:
目的: 比较静脉注射重组人脑钠尿肽(recombinant human brain natriuretic peptide,rhBNP)对伴有不同水钠潴留程度的急性失代偿心力衰竭（ADHF）患者的血流动力学作用及临床疗效。方法： 我院40例ADHF住院患者按水钠潴留程度分为试验组（中重度者，20例）和对照组（轻度者，20例），各组再随机抽取10例应用Swan-Ganz导管进行血流动力学监测，记录给药前及给药后0.5、1、3、6及24 h肺毛细血管楔压(PCWP)、肺动脉压(PAP)和右房压(RAP)并通过热敏稀释法测定心排出量（CO），计算心脏指数(CI)。所有患者均给抗心力衰竭治疗并给予rhBNP,首先以2 μg/kg静脉冲击,随后以0.01 μg/(kg·min)连续静脉滴注24 h，记录两组患者给药前及给药后0.5、1、3、6及24 h的呼吸困难及整体临床状况改善程度,以及用药后24 h液体出入量。结果： 与对照组比较，试验组患者呼吸困难及整体临床状况改善更明显，并伴随更佳的利尿作用［（2.7±0.8） L vs. （1.7±0.4） L，P=0.01］。试验组PCWP及RAP下降较迅速、明显且稳定持久，两组间PAP比较无统计学差异。两组CI比较组内及组间均无明显统计学差异。结论： 伴有中重度水钠潴留的ADHF患者较伴有轻度水钠潴留的患者应用rhBNP治疗有更好的急性血流动力学效应和临床效果,可能是rhBNP临床使用的最佳人群。
Abstract:
AIM: To compare the effect of intravenous infusion of recombinant human brain natriuretic peptide (rhBNP) on the hemodynamic profile and its clinical efficacy in patients with acute decompensated heart failure (ADHF). METHODS: Forty ADHF patients enrolled in our hospital were randomized equally to catheter group where hemodynamic changes were monitored with Swan-Ganz and noncatheter group (n=20 in each group). Pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP) and right atrial pressure (RAP) were recorded and cardiac output (CO) and cardiac index (CI) were assessed by heat-sensitive dilution method before drug administration and 0.5, 1, 3, 6 and 24 h after drug administration. Patients were divided into experiment group and control group and all patients received rhBNP with an initial i.v. bolus of 2 μg/kg followed by continuous i.v. titration of 0.01 μg/(kg·min) for 24 h. Dyspnea, overall symptom improvement in clinical conditions and fluid input and output were recorded before and 0.5, 1, 3, 6 and 24 h after drug administration. RESULTS: The alleviation of dyspnea and overall symptoms were more significant in experimental group compared to those in control group, accompanied by enhanced natriuretic effect ［(2.7±0.8) L vs.(1.7±0.4) L, P=0.01］. Patients in the experiment group experienced more rapid, apparent, stable and long-lasting declines in PCWP and RAP, with significant difference between groups. No significant intergroup difference was found in PAP between groups and no inter- and intra-group significant differences were observed in CI. CONCLUSION: Compared with ADHF patients with less severe H2O/Na+ retention, ADHF patients with more serious H2O/Na+ retention have more favorable acute hemodynamic profile and better clinical response to rhBNP treatment. ADHF patients with severe H2O/Na+ retention may be the optimal target population for clinical application of rhBNP treatment.

参考文献/References

［1］Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure［J］. Drugs, 2003, 63(1):47－70.

［2］Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide ( human B-type natriuretic peptide)in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group［J］. J Am Coll Cardiol, 1999, 34(1):155-162.

［3］ Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure［J］. J Am Coll Cardiol, 2002, 39(5):798-803.

［4］重组人脑利钠肽临床研究协作组． 重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究［J］．中华心血管病杂志， 2006，34（3）： 222-225．

［5］Yale SH, Mazza JJ. Approach to diagnosing lower extremity edema［J］. Compr Ther, 2001, 27(3):242-252.

［6］ Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial［J］. JAMA, 2002, 287(12):1531-1540.

［7] Pang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach［J］. Eur Heart J, 2008, 29(6):816-824.

［8］ Colucci WS, Elkayam E, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide,in the treatment of decompensated heart failure［J］. N Engl J Med, 2000, 343(4):246-253.

[9] Kawakami R, Saito Y, Kishimoto I, et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction［J］. Circulation, 2004, 110(21):3306-3312.

[10]Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure［J］. JAMA, 2002, 287(5):628-640.

[11]Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure［J］. J Am coll Cardiol, 2003, 41(10):1797-1804.

[12]李世强，傅向华，刘君，等. 静脉注射重组人脑利钠肽对急性心肌梗死伴心力衰竭患者的急性血流动力学效应的研究［J］． 中华心血管病杂志， 2006， 34（1）：23-27．

备注/Memo

备注/Memo:
收稿日期：2010-03-31.通讯作者：曹丰,教授,主要从事冠心病的诊断与治疗的研究Email:wind8828@gmail.com 作者简介：陶博，硕士生Email:tao_doc2008@yahoo.com.cn
更新日期/Last Update: 2010-06-22